Comparative study of mifepristone plus vaginal misoprostol versus vaginal misoprostol alone for second-trimester medical abortion
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20262529Keywords:
Second-trimester abortion, Mifepristone, Misoprostol, Induction-abortion interval, Medical termination of pregnancyAbstract
Background: Misoprostol is widely used for cervical ripening and uterine contractions, while mifepristone priming improves uterine sensitivity to prostaglandins and may enhance treatment efficiency. The present study compared the efficacy and safety of mifepristone plus vaginal misoprostol versus vaginal misoprostol alone for second-trimester termination of pregnancy (14-20 weeks).
Methods: This prospective comparative study included 150 women with singleton pregnancies between 14 and 20 weeks, allocated into two equal groups (n=75 each). Group 1 (Mife+Miso) received mifepristone 200 mg orally, followed after 36 hours by vaginal misoprostol 800 µg, then 400 µg vaginally every 3 hours up to four doses or until expulsion. Group 2 (Miso alone) received vaginal misoprostol 800 µg, followed by 400 µg every 3 hours up to four doses or until abortion occurred. Participants were monitored for expulsion, adverse effects, and complications; incomplete/failed abortions were managed with appropriate additional interventions.
Results: Baseline characteristics were comparable (mean age 24.43±5.13 vs 24.12±5.00 years; p=0.711). Complete abortion occurred in 90.7% of group 1 versus 65.3% of group 2 (p=0.0005), and overall success (complete abortion) remained significantly higher in group 1 (p=0.0004). The mean induction–abortion interval was significantly shorter with the combination regimen (7.38±2.60 vs 9.97±3.67 hours; p<0.001), with more women aborting within ≤8 hours (66.7% vs. 41.3%; p=0.003). The mean total misoprostol dose was lower in Group 1 (1413.33±368.10 vs. 1850.67±370.67 µg; p<0.001), and dose-category distribution differed significantly (p<0.001).
Conclusions: Mifepristone priming followed by vaginal misoprostol was more effective and faster than vaginal misoprostol alone for second-trimester medical abortion.
References
Mekie M, Fenta SM, Ferede WY, Yehuala ED, Dagnaw EH, Ayele AD, et al. The magnitude of second-trimester induced abortion and associated factors in Ethiopia: a systematic review and meta-analysis. Front Glob Womens Health. 2025;6:1535329.
World Health Organization. Abortion care guideline. Geneva: WHO; 2022.
Whitehouse K, Brant A, Fonhus MS, Lavelanet A, Ganatra B. Medical regimens for abortion at 12 weeks and above: a systematic review and meta-analysis. Contracept X. 2020;2:100037 .
Karena ZV, Shah H, Vaghela H, Chauhan K, Desai PK, Chitalwala AR. Clinical Utility of Mifepristone: Apprising the Expanding Horizons. Cureus. 2022;14(8):28318.
Aiob A, Gumin D, Abu Shqara R, Sgayer I, Lowenstein L, Sharon A. Short-Interval Mifepristone-Misoprostol Versus Misoprostol Alone for Second-Trimester Abortion: A Retrospective Observational Study. Cureus. 2026;18(2):103544.
Touval O, Ellert A, Daykan Y, Schonman R, Klein Z, Yagur Y. The efficacy of mifepristone-misoprostol regimen versus misoprostol-only for medication abortion at 22 + 0/7 to 30 + 0/7 weeks' gestation. Arch Gynecol Obstet. 2025;311(3):749-56.
Saini A, Bedi PK, Bhagat N.Comparative effectiveness of simultaneous administration of mifepristone and misoprostol versus interval regimen of mifepristone followed by misoprostol 12 hours apart in second trimester medical abortion.Int J Reprod Contracept Obstet Gynecol. 2018;7:2449-54.
Sahoo I, Abichandani R. Role of mifepristone in preinduction cervical ripening and induction of labour at term: an observational study. Int J Reprod Contracept Obstet Gynecol. 2023;12:3339-42.
Ngoc NTN, Shochet T, Raghavan S, Blum J, Nga NTB, Minh NTH, et al. Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: a randomized controlled trial. Obstet Gynecol. 2011;118:601-8.
Saharan S, Rastogi R, Sharma A. Prospective Comparative Study of Misoprostol Alone Versus Mifepristone Plus Misoprostol for Second-Trimester Pregnancy Termination. J Obstet Gynaecol India. 2024;74(6):498-504.
Zwerling B, Edelman A, Jackson A, Prabhu M, Taylor D, Taylor J, et al. Society of Family Planning clinical recommendation: medication abortion between 14 0/7 and 27 6/7 weeks of gestation. Contraception. 2024;129:110143.
Chavhan VM, Hol K, Sasane A, Dhenge V.Prospective comparative study of misoprostol alone versus mifepristone plus misoprostol for second-trimester pregnancy termination. Int J Reprod Contracept Obstet Gynecol. 2026;15:906-10.
Arora C, Yadav K, Samaria M, Benwal DK. Comparative study of “mifepristone plus vaginal misoprostol” versus “vaginal misoprostol” for second trimester (13-20 weeks) abortion at a tertiary care centre in Western India. Int J Clin Obstet Gynaecol. 2022;6(3):41-4.
Akkenapally PL. A Comparative Study of Misoprostol Only and Mifepristone Plus Misoprostol in Second Trimester Termination of Pregnancy. J Obstet Gynaecol India. 2016;66(1):251-7.
Soren SN, Dash PK. A comparative study of mifepristone and misoprostol versus misoprostol alone in mid trimester termination of pregnancy. J. Evid. Based Med. Healthc. 2018;5(3):255-9.
Aiob A, Gumin D, Abu Shqara R, Sgayer I, Lowenstein L, Sharon A. Short-Interval Mifepristone-Misoprostol Versus Misoprostol Alone for Second-Trimester Abortion: A Retrospective Observational Study. Cureus. 2026;18(2):103544.
Hill MG, Oyston C, Wise MR, Cronin R, Tamati M, Toldi G, Sadler L. Mifepristone versus placebo to increase the rate of spontaneous labour in people with a prior caesarean: a double-blind randomised controlled trial (Mi-labourTrial). Trials. 2025;26(1):570.
Braverman M, Dayan-Schwartz A, Ben-David Y, Kachta O, Zafran N. Early Pregnancy Termination with Mifepristone and Misoprostol: Concurrent vs. 48-Hour Interval Administration in a Randomized Controlled Trial. J Clin Med. 2025;14(21):7616.
Downloads
Published
How to Cite
Issue
Section
